BCG Vaccine Protection from Severe Coronavirus Disease 2019 (COVID19)
Escobar, L. E.; Molina-Cruz, A.; Barillas-Mury, C.
Show abstract
A series of epidemiological explorations has suggested a negative association between national BCG vaccination policy and the prevalence and mortality of COVID-19. However, these comparisons are difficult to validate due to broad differences between countries such as socioeconomic status, demographic structure, rural vs. urban settings, time of arrival of the pandemic, number of diagnostic tests and criteria for testing, and national control strategies to limit the spread of COVID-19. We review evidence for a potential biological basis of BCG cross-protection from severe COVID-19, and refine the epidemiological analysis to mitigate effects of potentially confounding factors (e.g., stage of the COVID-19 epidemic, development, rurality, population density, and age structure). A strong correlation between the BCG index, an estimation of the degree of universal BCG vaccination deployment in a country, and COVID-19 mortality in different socially similar European countries was observed (r2 = 0.88; p = 8x10-7), indicating that every 10% increase in the BCG index was associated with a 10.4% reduction in COVID-19 mortality. Results fail to confirm the null hypothesis of no-association between BCG vaccination and COVID-19 mortality, and suggest that BCG could have a protective effect. Nevertheless, the analyses are restricted to coarse-scale signals and should be considered with caution. BCG vaccination clinical trials are required to corroborate the patterns detected here, and to establish causality between BCG vaccination and protection from severe COVID-19. Public health implications of a plausible BCG cross-protection from severe COVID-19 are discussed. Significance StatementThe COVID-19 pandemic is one of the most devastating in recent history. The bacillus Calmette-Guerin (BCG) vaccine against tuberculosis also confers broad protection against other infectious diseases, and it has been proposed that it could reduce the severity of COVID-19. This epidemiological study assessed the global linkage between BCG vaccination and COVID-19 mortality. Signals of BCG vaccination effect on COVID-19 mortality are influenced by social, economic, and demographic differences between countries. After mitigating multiple confounding factors, several significant associations between BCG vaccination and reduced COVID-19 deaths were observed. This study highlights the need for mechanistic studies behind the effect of BCG vaccination on COVID-19, and for clinical evaluation of the effectiveness of BCG vaccination to protect from severe COVID-19.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Sex differences in vaccine induced immunity and protection against Mycobacterium tuberculosis 90%
- Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including early variants of concern: a test-negative design, British Columbia, Canada 89%
- Estimated population-level impact of pneumococcal conjugate vaccines against all-cause pneumonia mortality among unvaccinated age groups in five Latin American countries 89%
Similar papers in this journal
- Efficacy of vaccination against severe COVID-19 in relation to Delta variant and time since second dose: the REACT-SCOT case-control study 91%
- The Natural History of Untreated Pulmonary Tuberculosis in Adults: A Systematic Review and Meta-Analysis 91%
- Concise whole blood transcriptional signatures for incipient tuberculosis: A systematic review and patient-level pooled meta-analysis 88%
Similar papers in this journal
- Significantly Improved COVID-19 Outcomes in Countries with Higher BCG Vaccination Coverage: A Multivariable Analysis 92%
- COVID-19 vaccine uptake and effectiveness by time since vaccination in the Western Cape province, South Africa: An observational cohort study during 2020-2022 92%
- Effectiveness of ChAdOx1 nCoV-19 Corona Virus Vaccine (Covishield™) in preventing SARS-CoV2 infection, Chennai, Tamil Nadu, India, 2021 91%
Similar papers in this journal
- The impact of vaccination on preventing long COVID in the Omicron era: a systematic review and meta-analysis 92%
- Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against Omicron in Brazil 92%
- Protection of COVID-19 vaccination and previous infection against Omicron BA.1 and Delta SARS-CoV-2 infections, the Netherlands, 22 November 2021- 19 January 2022 91%
Similar papers in this journal
- Activate-2: A Double-Blind Randomized Trial Of Bcg Vaccination Against Covid19 In Individuals At Risk 93%
- Vaccination history for diphtheria and tetanus is associated with less severe COVID-19 92%
- Facing the Omicron variant – How well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.